 Home > Active Ingredient News > Antitumor Therapy > Gu Tianning, Hu Yongxian, Zhejiang University, et al.: B-cell malignant tumors recur after CAR-T cell therapy: challenges and future

Gu Tianning, Hu Yongxian, Zhejiang University, et al.: B-cell malignant tumors recur after CAR-T cell therapy: challenges and future

 Last Update: 2022-11-05
 Source: Internet
 Author: User

Tags

comprehensive research group

practice journal

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Content introduction

Chinese Summary:

Outline:

As a new type of cellular immunotherapy, chimeric antigen receptor T (CAR-T) cell therapy has greatly changed the landscape of cancer treatment, especially in
hematologic malignancies.
However, recurrence after CAR-T cell therapy is still one of
the main obstacles affecting its widespread clinical application.
The intrinsic characteristics and strong adaptability of tumor cells are an important cause of
recurrence.
Due to the existence of special CAR structure, the unique biological functions of CAR-T cells also affect the treatment effect
.
In addition, the intricate interactions in the tumor microenvironment profoundly affect the function and clinical prognosis
of CAR-T cells.
Therefore, based on the latest findings, this review focuses on the recurrence of B-cell malignancies after CAR-T cell treatment from the perspectives of tumor cells, CAR-T cells and tumor microenvironment, and discusses the corresponding basic and clinical strategies in the future to provide a comprehensive understanding and help improve research and clinical application
.

Keyword groups:

chimeric antigen receptor T (CAR-T); B-cell malignancies; Mechanism of recurrence; tactics

Author:

Tianning GU, Meng ZHU, He HUANG, Yongxian HU

Citation format of this article:

Tianning GU, Meng ZHU, He HUANG, Yongxian HU.
Relapse after CAR-Tcell therapy in B-cell malignancies: challenges and future approaches[J].
Journal ofZhejiang University Science B, 2022, 23(10): 793-811.

https://doi.
org/10.
1631/jzus.
B2200256

Essential introduction to this article:

Full text download address: https://jzus.
zju.
edu.
cn/oldversion/opentxt.
php?doi=10.
1631/jzus.
B2200256

About this journal

Journal of Zhejiang University (English Edition) Series B: Biomedicine and Biotechnology, referred to as JZUS-B, is a comprehensive English monthly journal
of biology.
JZUS-B has been included in SCI-E since 2008, with a latest impact factor of 5.
552, and has been searched
by well-known domestic and foreign platforms such as MEDLINE/PubMed, PMC, Scopus, BA, BIOSIS Previews, etc.

JZUS-B receives articles in life sciences, medicine, pharmacy, biochemistry, biotechnology and bioengineering, agronomy, ecology, and zoology
.
Article types include Review, Article, Perspective, Viewpoint, Editorial, Correspondence, etc
.

The journal has always implemented a strict international peer review mechanism, with an average review period of 42 days and an average acceptance time of 53 days
.
After acceptance, the article will be immediately online in Press and will generally be officially published
within 2 months.

"Content-oriented, flexible form" is the characteristic of
this journal.
JZUS-B welcomes outstanding scholars at home and abroad to submit the latest scientific research achievements, controversial topics, review papers and organize the publication of hot albums
.

Journal Springer homepage:

style="outline: 0px;max-width: 536px;box-sizing: border-box;min-height: 14px;overflow-wrap: break-word !important;" _msthash="251726" _msttexthash="586040">Online Submission Address:

style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;">

Zhejiang University Journal English version is a number of English academic journals of the general name, the scope of collection covers all directions of science, engineering, agriculture and medicine, welcome to submit to our journal, you can pay attention to our journal public number zdxbywb for more information
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.